This study is recruiting patients diagnosed with rapid-onset dystonia-parkinsonism (RDP). RDP is a rare movement disorder. It has symptoms of both dystonia (lasting muscle contractions) and Parkinson’s Disease (presence of tremor in one hand and a stiffness or slowing of movement). Patients may develop RDP suddenly or gradually over time. Read More

1) Patients with known/suspected RDP gene mutation OR those who have been identified as carriers/family members of someone with an RDP gene mutation 2)Patients who were previously enrolled in an earlier version of this study 3) 18 months of age or older 4) Access to Wi-Fi and a smart device (for example, a smartphone, laptop, tablet)

This study is for children ages 7 – 17 years old admitted to the Oishei Children’s Hospital emergency room (ER) who are experiencing nausea/vomiting. The goal of the study is to see if a different treatment (inhaled isopropyl alcohol) works better than the medication typically used (Zofran) for treating nausea/vomiting in pediatric patients. Read More

1. 7-17 years old

2. Chief complaint of nausea or vomiting

3. Weight >=15 kg (~33lbs)

4. BARF (nausea severity score) >=4/10

5. Admitted to the Oishei Children's Hospital emergency room

This study is being used to evaluate a new troponin blood test. Troponin blood tests are used in emergency departments as part of the diagnosis for heart attack. Patients presenting to the emergency department with chest pain or heart attack equivalent symptoms will be invited to participate. Blood draws will occur 5 times during the patient's emergency department visit. The results of the blood test will not be available to the treating provider, and will have no effect on patient care. Read More

1. Patients seeking emergency care in participating emergency department

2. Signed Informed Consent

3. Age: 20 or more years

4. Subjects demonstrating symptoms suggestive of acute coronary syndrome and/or myocardial ischemia or Asymptomatic subjects or patients with atypical symptoms in whom myocardial infarction is being suspected

5. Troponin or other cardi...

This study enrolls people who have head and neck cancer or tumor. The purpose of this study is to learn about whether levels of HPV (Human Papillomavirus) and a protein (P16) are related to the way people respond to treatment for head and neck cancer. Read More

-Patients at least 18 years of age.
-Patients who have been diagnosed with head and neck squamous cell carcinoma.
-Patients who have a pre-treatment biopsy of a pathologically confirmed p16/HPV positive tumor.

For 18-45 year old women undergoing gynecology surgery at Kaleida Health. A sliver of tissue and a tablespoon of fluid will be removed from womb lining which will take less than 5 minutes. This tissue and pelvic fluid will be used to examine cells, and measure hormones / inflammatory proteins. Patients will also be told whether or not there is endometriosis. Read More

-Reproductive age women (18-45 years old)
-Regular menstrual cycles
-Undergoing indicated gynecological surgery, including tubal sterilization, evaluation of pelvic pain or pelvic mass

This clinical trial is exploring the use of an investigational drug (sGC stimulator vericiguat/MK-1242) in patients with chronic heart failure. Specifically, trial doctors are interested in assessing the safety of this drug and if it works well to lower some of the risks of heart failure. All participants will be able to stay on their current heart failure medication during the 2-year trial period. Read More

1) History of chronic stable, NYHA class II to IV CHF 2) NT-proBNP 600 - 6000 3) LVEF of <40% assessed within 12 months before randomization

The goal of the UB Eating Among Teens Study (UB EATS) is to measure eating behaviors and neighborhood and household factors in 11 - 14-year-olds over the course of 3 years. Participation involves 7 visits to the UB Nutrition and Health Research Lab on South Campus over the 3-year period to answer questionnaires and eat snack foods. Low and middle-income families are encouraged to apply. Read More

-Adolescents ages 11 to 14

-Low to moderate income households

-No medical conditions or medications that impact appetite

-No allergies to study foods such as cookies, candy and potato chips

-Planning to live in the Western New York area for the next two years

-Willing to attend baseline and follow-up visits at a local research center

-Ad...

The goal of this study is to evaluate the safety, effectiveness and tolerability of a drug compound (AVP- 786) for the treatment of agitation associated with Alzheimer’s Disease. Alzheimer’s Disease causes loss of brain cells and problems with memory, thinking and behavior. Agitated behaviors, such as irritability and restlessness, physical and verbal aggression, and pacing and wandering are major problems in this condition, can be difficult to manage, and can impact your quality of life. AVP-786 is targeted at treating your agitation behaviors. Caregivers are being asked to take part in this research study because the participants may require assistance to complete study procedures and/or attend study visits. Participation in this study will last for approximately 20 weeks and include site visits throughout the study. Read More

Patients 50 to 90 years of age (inclusive) with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to screening that interferes with daily routine per the Investigator's judgment, and who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions. A...

Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More

1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens

We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More

1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
4) Cisplatin-ineligible